23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...

Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.

The once-thriving consumer genetic-testing company 23andMe is struggling to stay afloat — raising concerns about what might happen to its customers’ data and the broader industry. The decline ...

The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer ...